Jordan Holmes, MD
Gastroenterology · Omaha, NENPI 1518130624
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 28.2% of the total. Reporting peaked in 2022 at $891 and has fallen 67.3% since, to $291 in 2025. That places this record below the midpoint for gastroenterology clinicians in NE, where the typical reported total is $2,374.
Across 151 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$749
- Takeda Pharmaceuticals U.S.A., Inc.$277
- Gilead$245
- Johnson & Johnson$185
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$183
- Madrigal Pharmaceuticals$162
- plus $858 from 19 others
What the payments were for
- Food & beverage$2,63099%
- Other$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $749 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $277 |
| Gilead | 12 | $245 |
| Johnson & Johnson | 11 | $185 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $183 |
| Madrigal Pharmaceuticals | 8 | $162 |
| Sanofi | 7 | $159 |
| Bristol Myers Squibb | 8 | $125 |
| Boston Scientific | 2 | $84 |
| Amgen | 4 | $76 |
| Ferring Pharmaceuticals Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 3 | $47 |
| Boehringer Ingelheim | 2 | $46 |
| Intercept Pharmaceuticals, Inc. | 3 | $46 |
| Ironwood Pharmaceuticals, Inc | 2 | $34 |
| Merck | 2 | $30 |
| Covidien LP | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Exact Sciences | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Organon | 1 | $17 |
| Welch Allyn | 1 | $17 |
| QOL Medical, LLC | 1 | $17 |
| Pfizer | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
How this compares
$2,659 in reported general payments places this provider in the 50th percentile of 89 gastroenterology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $74,927 |
| LinzessLinaclotide | 37 | $25,096 |
| CreonLipase/Protease/Amylase | 12 | $20,820 |
| MotegrityPrucalopride Succinate | 16 | $13,960 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 246 | $5,049 |
| Mesalamine | 17 | $3,993 |
| Pantoprazole Sodium | 383 | $3,628 |
| Colestipol Hcl | 46 | $3,399 |
| Mesalamine ErMesalamine | 14 | $2,301 |
| Omeprazole | 92 | $1,256 |
| Esomeprazole Magnesium | 29 | $820 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 13 | $758 |
| Sucralfate | 18 | $495 |
| Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg | 31 | $481 |
| Dicyclomine Hcl | 40 | $458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $749 | $45,91749 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $277 | $13,96016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 89 gastroenterology providers in Nebraska.
Other gastroenterology in Omaha
- Benjamin HallOmaha$154K
- Sandeep MukherjeeOmaha$145K
- Rowen ZettermanOmaha$119K
- Derrick EicheleOmaha$54K
- Joshua EvansOmaha$34K
- Michael SchaferOmaha$30K
- Peter MannonOmaha$30K
- Helen Fasanya-UptagraftOmaha$26K
- Rajani RangrayOmaha$15K
- Grant HutchinsOmaha$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.